Mydecine Innovations Group (MYCO.C) announced that they have received approval from Health Canada to significantly expand their cultivation capacity at their Canadian Current Good Manufacturing Practice (cGMP) facility at…
Search Results for: MYCO.C
Mydecine (MYCO.C), an upcoming biopharma and life sciences company advocating for the therapeutic use of psychedelic mushrooms, has successfully completed the world’s first legal international export of psilocybin mushrooms….
Mydecine Innovations Group (MYCO.C) expanded their relationship with Applied Pharmaceutical Innovation (API) to include the University of Alberta in support of multiple drug development and clinical trials, according to…
Mydecine Innovations Group (MYCO.C) announced that they were sponsoring a study called “The neurocognitive effects of low dose psychoactive substances,” at Macquary University in Australia today, according to a…
Mydecine Innovations Group (MYCO.C) launched Mindleap Health, a digital telehealth mobile application today. The intent behind Mindleap is to increase access to mental health services and provide analytics and…
Mydecine Innovations Group’s (MYCO.C) subsidiary Mindleap Health expanded its digital therapeutic services, dealing specifically with addiction, by adding three new programs to its platform. This company is no stranger…
War is a part of human nature. It’s the greatest driver of human innovation, and if we’re inclined to be cynical we could state that it’s the key reason…
Mydecine Innovations Group (MYCO.C) signed a non-binding letter of intent to acquire NeuroPharm, a Canadian-based healthcare company involved in the nascent shroom-space earlier this week. The all-share deal will…
RethinkX, a think tank which analyzes industry-disrupting technologies, has published a report about new sources of protein at a time when hamburgers may be costlier than advertised. Methane from…